Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2023; 13(14):5017-5056. doi:10.7150/thno.78876 This issue Cite

Review

Targeting cullin neddylation for cancer and fibrotic diseases

Zhang-Xu He1,2#, Wei-guang Yang3#, Dan Zengyangzong2, Ge Gao2, Qian Zhang2, Hong-Min Liu2, Wen Zhao2✉, Li-Ying Ma2,4,5✉

1. Pharmacy College, Henan University of Chinese Medicine, 450046, Zhengzhou, China.
2. State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
3. Children's hospital affiliated of Zhengzhou university; Henan children's hospital; Zhengzhou children's hospital, Henan Zhengzhou 450000, China.
4. China Meheco Topfond Pharmaceutical Co., Zhumadian 463000, China.
5. Key Laboratory of Cardio-cerebrovascular Drug, Henan Province, Zhumadian 463000, China.
#: These authors contribute equally to this work.
*: These senior authors contribute equally to this work.

✉ Corresponding author: Zhao Wen, Ph.D, zhaowen100com and Ma Li-Ying, Ph.D, maliyingedu.cn.

Citation:
He ZX, Yang Wg, Zengyangzong D, Gao G, Zhang Q, Liu HM, Zhao W, Ma LY. Targeting cullin neddylation for cancer and fibrotic diseases. Theranostics 2023; 13(14):5017-5056. doi:10.7150/thno.78876. https://www.thno.org/v13p5017.htm
Other styles

File import instruction

Abstract

Graphic abstract

Protein neddylation is a post-translational modification, and its best recognized substrates are cullin family proteins, which are the core component of Cullin-RING ligases (CRLs). Given that most neddylation pathway proteins are overactivated in different cancers and fibrotic diseases, targeting neddylation becomes an emerging approach for the treatment of these diseases. To date, numerous neddylation inhibitors have been developed, of which MLN4924 has entered phase I/II/III clinical trials for cancer treatment, such as acute myeloid leukemia, melanoma, lymphoma and solid tumors. Here, we systematically describe the structures and biological functions of the critical enzymes in neddylation, highlight the medicinal chemistry advances in the development of neddylation inhibitors and propose the perspectives concerning targeting neddylation for cancer and fibrotic diseases.

Keywords: Cullin neddylation, Inhibitors, Cancer, Fibrotic diseases

Citation styles

APA
He, Z.X., Yang, W.g., Zengyangzong, D., Gao, G., Zhang, Q., Liu, H.M., Zhao, W., Ma, L.Y. (2023). Targeting cullin neddylation for cancer and fibrotic diseases. Theranostics, 13(14), 5017-5056. https://doi.org/10.7150/thno.78876.

ACS
He, Z.X.; Yang, W.g.; Zengyangzong, D.; Gao, G.; Zhang, Q.; Liu, H.M.; Zhao, W.; Ma, L.Y. Targeting cullin neddylation for cancer and fibrotic diseases. Theranostics 2023, 13 (14), 5017-5056. DOI: 10.7150/thno.78876.

NLM
He ZX, Yang Wg, Zengyangzong D, Gao G, Zhang Q, Liu HM, Zhao W, Ma LY. Targeting cullin neddylation for cancer and fibrotic diseases. Theranostics 2023; 13(14):5017-5056. doi:10.7150/thno.78876. https://www.thno.org/v13p5017.htm

CSE
He ZX, Yang Wg, Zengyangzong D, Gao G, Zhang Q, Liu HM, Zhao W, Ma LY. 2023. Targeting cullin neddylation for cancer and fibrotic diseases. Theranostics. 13(14):5017-5056.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use